{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:32:51Z","timestamp":1790710371343,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40272-019-00325-x","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T23:30:18Z","timestamp":1549582218000},"page":"15-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["A Practical Guide to Treatment of Childhood Absence Epilepsy"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-9972","authenticated-orcid":false,"given":"Sudha Kilaru","family":"Kessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"McGinnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"325_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/j.1528-1157.1995.tb01060.x","volume":"36","author":"P Loiseau","year":"1995","unstructured":"Loiseau P, Duch\u00e9 B, P\u00e9despan JM. Absence epilepsies. Epilepsia. 1995;36:1182\u20136.","journal-title":"Epilepsia"},{"key":"325_CR2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1528-1157.2000.tb00246.x","volume":"41","author":"PE Waaler","year":"2000","unstructured":"Waaler PE, Blom BH, Skeidsvoll H, Mykletun A. Prevalence, classification, and severity of epilepsy in children in Western Norway. Epilepsia. 2000;41:802\u201310.","journal-title":"Epilepsia"},{"key":"325_CR3","doi-asserted-by":"crossref","unstructured":"L C et al. Differential diagnosis of staring spells in children: a video-EEG study. Pediatr Neurol. 14:199\u2013202 (1996).","DOI":"10.1016\/0887-8994(96)00080-X"},{"key":"325_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0022-3476(98)70108-8","volume":"133","author":"F Rosenow","year":"1998","unstructured":"Rosenow F, et al. Staring spells in children: descriptive features distinguishing epileptic and nonepileptic events. J Pediatr. 1998;133:660\u20133.","journal-title":"J Pediatr"},{"key":"325_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/ana.410210308","volume":"21","author":"GL Holmes","year":"1987","unstructured":"Holmes GL, McKeever M, Adamson M. Absence seizures in children: clinical and electroencephalographic features. Ann Neurol. 1987;21:268\u201373.","journal-title":"Ann Neurol"},{"key":"325_CR6","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1212\/WNL.0b013e3182a9f3ca","volume":"81","author":"D Masur","year":"2013","unstructured":"Masur D, et al. Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy. Neurology. 2013;81:1572\u201380.","journal-title":"Neurology"},{"key":"325_CR7","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1212\/WNL.0000000000004514","volume":"89","author":"RC Shinnar","year":"2017","unstructured":"Shinnar RC, et al. Pretreatment behavior and subsequent medication effects in childhood absence epilepsy. Neurology. 2017;89:1698\u2013706.","journal-title":"Neurology"},{"key":"325_CR8","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1111\/epi.13222","volume":"56","author":"J Larsen","year":"2015","unstructured":"Larsen J, et al. The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. Epilepsia. 2015;56:e203\u20138.","journal-title":"Epilepsia"},{"key":"325_CR9","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1212\/WNL.45.8.1469","volume":"45","author":"DC Reutens","year":"1995","unstructured":"Reutens DC, Berkovic SF. Idiopathic generalized epilepsy of adolescence: are the syndromes clinically distinct? Neurology. 1995;45:1469\u201376.","journal-title":"Neurology"},{"key":"325_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1212\/01.wnl.0000228257.60184.82","volume":"67","author":"LG Sadleir","year":"2006","unstructured":"Sadleir LG, Farrell K, Smith S, Connolly MB, Scheffer IE. Electroclinical features of absence seizures in childhood absence epilepsy. Neurology. 2006;67:413\u20138.","journal-title":"Neurology"},{"key":"325_CR11","doi-asserted-by":"crossref","unstructured":"Wheless JW, Clarke DF, Carpenter D Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol. 20:59\u201360 (2005).","DOI":"10.1177\/088307380502000101"},{"key":"325_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa0902014","volume":"362","author":"TA Glauser","year":"2010","unstructured":"Glauser TA, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362:790\u20139.","journal-title":"N Engl J Med"},{"key":"325_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/epi.12028","volume":"54","author":"TA Glauser","year":"2013","unstructured":"Glauser TA, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54:141\u201355.","journal-title":"Epilepsia"},{"key":"325_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1212\/WNL.0000000000005755","volume":"91","author":"AM Kanner","year":"2018","unstructured":"Kanner AM, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91:74\u201381.","journal-title":"Neurology"},{"key":"325_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/ana.410250610","volume":"25","author":"DA Coulter","year":"1989","unstructured":"Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989;25:582\u201393.","journal-title":"Ann Neurol"},{"key":"325_CR16","doi-asserted-by":"crossref","unstructured":"Buchanan RA, Fernandez L, Kinkel AW Absorption and elimination of ethosuximide in children. J Clin Pharmacol J. 9:393\u20138.","DOI":"10.1177\/009127006900900607"},{"key":"325_CR17","doi-asserted-by":"crossref","unstructured":"Battino D, Estienne M, Avanzini G Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin. Pharmacokinet. 29, 257\u2013286 (1995).","DOI":"10.2165\/00003088-199529040-00005"},{"key":"325_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2165\/00003088-197904010-00004","volume":"4","author":"GA Smith","year":"1979","unstructured":"Smith GA, McKauge L, Dubetz D, Tyrer JH, Eadie MJ. Factors influencing plasma concentrations of ethosuximide. Clin Pharmacokinet. 1979;4:38\u201352.","journal-title":"Clin Pharmacokinet"},{"key":"325_CR19","first-page":"1128","volume":"247","author":"BF Bourgeois","year":"1988","unstructured":"Bourgeois BF. Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction. J Pharmacol Exp Ther. 1988;247:1128\u201332.","journal-title":"J Pharmacol Exp Ther"},{"key":"325_CR20","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1528-1167.2009.02144.x","volume":"50","author":"A Crespel","year":"2009","unstructured":"Crespel A, Velizarova R, Agullo M, G\u00e9lisse P. Ethosuximide-induced de novo systemic lupus erythematosus with anti-double-strand DNA antibodies: a case report with definite evidence. Epilepsia. 2009;50:2003.","journal-title":"Epilepsia"},{"key":"325_CR21","first-page":"S74","volume":"32","author":"E Wyllie","year":"1990","unstructured":"Wyllie E, Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy. Epilepsia. 1990;32:S74\u20139.","journal-title":"Epilepsia"},{"key":"325_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1212\/WNL.0000000000003480","volume":"88","author":"A Cnaan","year":"2017","unstructured":"Cnaan A, et al. Second monotherapy in childhood absence epilepsy. Neurology. 2017;88:182\u201390.","journal-title":"Neurology"},{"key":"325_CR23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1528-1157.1984.tb05630.x","volume":"25","author":"D Johnston","year":"1984","unstructured":"Johnston D. Valproic acid: update on its mechanisms of action. Epilepsia. 1984;25:S1\u20134.","journal-title":"Epilepsia"},{"key":"325_CR24","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","volume":"48","author":"G Zaccara","year":"2007","unstructured":"Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48:1223\u201344.","journal-title":"Epilepsia"},{"key":"325_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/epi.13021","volume":"56","author":"T Tomson","year":"2015","unstructured":"Tomson T, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015;56:1006\u201319.","journal-title":"Epilepsia"},{"key":"325_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1212\/WNL.36.6.838","volume":"36","author":"C Camfield","year":"1986","unstructured":"Camfield C, Camfield P, Smith E, Tibbles JAR. Asymptomatic children with epilepsy: little benefit from screening for anticonvulsant-induced liver, blood, or renal damage. Neurology. 1986;36:838\u201341.","journal-title":"Neurology"},{"key":"325_CR27","doi-asserted-by":"crossref","unstructured":"AZ C, BD M, EC W Specific safety and tolerability considerations in the use of anticonvulsant medications in children. Drug Healthc Patient Saf 4:39\u201354 (2012).","DOI":"10.2147\/DHPS.S28821"},{"key":"325_CR28","doi-asserted-by":"crossref","unstructured":"Buoli M, Serati M, Botturi A, Altamura AC The risk of thrombocytopenia during valproic acid therapy: a critical summary of available clinical data. Drugs 18, (2018).","DOI":"10.1007\/s40268-017-0224-6"},{"key":"325_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1528-1157.1999.tb00805.x","volume":"40","author":"LM Frank","year":"1999","unstructured":"Frank LM, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia. 1999;40:973\u20139.","journal-title":"Epilepsia"},{"key":"325_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eplepsyres.2008.07.016","volume":"82","author":"GL Holmes","year":"2008","unstructured":"Holmes GL, et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res. 2008;82:124\u201332.","journal-title":"Epilepsy Res"},{"key":"325_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","volume":"25","author":"B Rambeck","year":"1993","unstructured":"Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet. 1993;25:433\u201343.","journal-title":"Clin Pharmacokinet"},{"key":"325_CR32","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1212\/01.wnl.0000261917.83337.db","volume":"68","author":"H Arif","year":"2007","unstructured":"Arif H, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68:1701\u20139.","journal-title":"Neurology"},{"key":"325_CR33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa0902014","volume":"362","author":"TA Glauser","year":"2010","unstructured":"Glauser TA, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362:790\u20139.","journal-title":"N Engl J Med"},{"key":"325_CR34","doi-asserted-by":"crossref","unstructured":"ES et al Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 35, 359\u2013367 (1994).","DOI":"10.1111\/j.1528-1157.1994.tb02445.x"},{"key":"325_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1592\/phco.19.6.437.31052","volume":"19","author":"C Chen","year":"1999","unstructured":"Chen C, Casale EJ, Duncan B, Culverhouse EH, Gilman J. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy. 1999;19:437\u201341.","journal-title":"Pharmacotherapy"},{"key":"325_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3303\/cet0917181","volume":"1\u201315","author":"SC Dijkman van","year":"2018","unstructured":"van Dijkman SC, de Jager NCB, Rauw\u00e9 WM, Danhof M. Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for dose optimisation in epilepsy patients. Clin. Pharmacokinet. 2018;1\u201315:56. https:\/\/doi.org\/10.3303\/cet0917181 .","journal-title":"Clin. Pharmacokinet."},{"key":"325_CR37","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","volume":"26","author":"MJ Brodie","year":"1997","unstructured":"Brodie MJ, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res. 1997;26:423\u201332.","journal-title":"Epilepsy Res"},{"key":"325_CR38","unstructured":"Hirsch E, Panayiotopoulos C. Childhood absence epilepsy and related syndromes. In: Bureau, R., Dravet, C., Genton, P., Tassinari C, Wolf P (eds) Epileptic syndromes in infancy, childhood, and adolescence. John Libbey Eurotext LTD, 2005, pp 315\u2013335"},{"key":"325_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/0883073812461943","volume":"28","author":"MS Perry","year":"2013","unstructured":"Perry MS, et al. Clobazam for the treatment of intractable epilepsy in children. J Child Neurol. 2013;28:34\u20139.","journal-title":"J Child Neurol"},{"key":"325_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2014.01.025","volume":"51","author":"J Klehm","year":"2014","unstructured":"Klehm J, et al. Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. Pediatr Neurol. 2014;51:60\u20136.","journal-title":"Pediatr Neurol"},{"key":"325_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","volume":"26","author":"R Sankar","year":"2012","unstructured":"Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26:229\u201344.","journal-title":"CNS Drugs"},{"key":"325_CR42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/seiz.2001.0655","volume":"11","author":"JH Cross","year":"2002","unstructured":"Cross JH. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure. 2002;11:406\u201310.","journal-title":"Seizure"},{"key":"325_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1600-0404.2010.01347.x","volume":"123","author":"JE Pi\u00f1a-Garza","year":"2011","unstructured":"Pi\u00f1a-Garza JE, Schwarzman L, Wiegand F, Hulihan J. A pilot study of topiramate in childhood absence epilepsy. Acta Neurol Scand. 2011;123:54\u20139.","journal-title":"Acta Neurol Scand"},{"key":"325_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.eplepsyres.2005.02.006","volume":"64","author":"A Wilfong","year":"2005","unstructured":"Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res. 2005;64:31\u20134.","journal-title":"Epilepsy Res"},{"key":"325_CR45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/0883073810376443","volume":"26","author":"LB Groomes","year":"2011","unstructured":"Groomes LB, et al. Do patients with absence epilepsy respond to ketogenic diets? J Child Neurol. 2011;26:160\u20135.","journal-title":"J Child Neurol"},{"key":"325_CR46","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1111\/j.1528-1167.2011.03394.x","volume":"53","author":"S Thammongkol","year":"2012","unstructured":"Thammongkol S, et al. Efficacy of the ketogenic diet: which epilepsies respond? Epilepsia. 2012;53:e55\u20139.","journal-title":"Epilepsia"},{"key":"325_CR47","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1528-1167.2010.02976.x","volume":"52","author":"C Fattore","year":"2011","unstructured":"Fattore C, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia. 2011;52:802\u20139.","journal-title":"Epilepsia"},{"key":"325_CR48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1469-8749.2008.03099.x","volume":"50","author":"A Verrotti","year":"2008","unstructured":"Verrotti A, et al. Levetiracetam in absence epilepsy. Dev Med Child Neurol. 2008;50:850\u20133.","journal-title":"Dev Med Child Neurol"},{"key":"325_CR49","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ejpn.2011.05.007","volume":"15","author":"S Auvin","year":"2011","unstructured":"Auvin S, et al. Aggravation of absence seizure related to levetiracetam. Eur J Paediatr Neurol. 2011;15:508\u201311.","journal-title":"Eur J Paediatr Neurol"},{"key":"325_CR50","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/088307389601100611","volume":"11","author":"V Trudeau","year":"1996","unstructured":"Trudeau V, et al. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol. 1996;11:470\u20135.","journal-title":"J Child Neurol"},{"key":"325_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1528-1167.2009.02233.x","volume":"50","author":"ER Somerville","year":"2009","unstructured":"Somerville ER. Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy). Epilepsia. 2009;50:31\u20136.","journal-title":"Epilepsia"},{"key":"325_CR52","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1528-1157.2001.02401.x","volume":"42","author":"E Wirrell","year":"2001","unstructured":"Wirrell E, Camfield C, Camfield P, Dooley J. Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy. Epilepsia. 2001;42:760\u20133.","journal-title":"Epilepsia"},{"key":"325_CR53","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/j.1528-1167.2005.00277.x","volume":"46","author":"S Grosso","year":"2005","unstructured":"Grosso S, et al. Childhood absence epilepsy: evolution and prognostic factors. Epilepsia. 2005;46:1796\u2013801.","journal-title":"Epilepsia"},{"key":"325_CR54","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ana.410130610","volume":"13","author":"P Loiseau","year":"1983","unstructured":"Loiseau P, et al. Long-term prognosis in two forms of childhood epilepsy: typical absence seizures and epilepsy with rolandic (centrotemporal) EEG foci. Ann Neurol. 1983;13:642\u20138.","journal-title":"Ann Neurol"},{"key":"325_CR55","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1212\/WNL.0b013e31829a3373","volume":"81","author":"D Dlugos","year":"2013","unstructured":"Dlugos D, et al. Pretreatment EEG in childhood absence epilepsy. Neurology. 2013;81:150\u20136.","journal-title":"Neurology"},{"key":"325_CR56","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/brain\/112.4.1039","volume":"112","author":"CP Panayiotopoulos","year":"1989","unstructured":"Panayiotopoulos CP, Obeid T, Waheed G. Differentiation of typical absence seizures in epileptic syndromes. A video EEG study of 224 seizures in 20 patients. Brain. 1989;112:1039\u201356.","journal-title":"Brain"},{"key":"325_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1212\/WNL.0000000000004226","volume":"89","author":"SK Kessler","year":"2017","unstructured":"Kessler SK, et al. Pretreatment seizure semiology in childhood absence epilepsy. Neurology. 2017;89:56.","journal-title":"Neurology"},{"key":"325_CR58","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.24886","volume":"81","author":"TA Glauser","year":"2017","unstructured":"Glauser TA, et al. Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Ann Neurol. 2017;81:444\u201353.","journal-title":"Ann Neurol"},{"key":"325_CR59","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1212\/WNL.47.4.912","volume":"47","author":"EC Wirrell","year":"1996","unstructured":"Wirrell EC, Camfield CS, Camfield PR, Gordon KE, Dooley JM. Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology. 1996;47:912\u20138.","journal-title":"Neurology"},{"key":"325_CR60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eplepsyres.2008.11.011","volume":"83","author":"PMC Callenbach","year":"2009","unstructured":"Callenbach PMC, et al. Long-term outcome of childhood absence epilepsy: Dutch Study of Epilepsy in Childhood. Epilepsy Res. 2009;83:249\u201356.","journal-title":"Epilepsy Res"},{"key":"325_CR61","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1212\/WNL.33.12.1590","volume":"33","author":"S Sato","year":"1983","unstructured":"Sato S, Dreifuss FE, Penry JK, Kirby DD, Palesch Y. Long-term follow-up of absence seizures. Neurology. 1983;33:1590\u20135.","journal-title":"Neurology"},{"key":"325_CR62","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1212\/WNL.26.8.788","volume":"26","author":"S Sato","year":"1976","unstructured":"Sato S, Dreifuss FE, Penry JK. Prognostic factors in absence seizures. Neurology. 1976;26:788\u201396.","journal-title":"Neurology"},{"key":"325_CR63","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12551","volume":"55","author":"AT Berg","year":"2014","unstructured":"Berg AT, Levy SR, Testa FM, Blumenfeld H. Long-term seizure remission in childhood absence epilepsy: might initial treatment matter? Epilepsia. 2014;55:551\u20137.","journal-title":"Epilepsia"},{"key":"325_CR64","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/j.1528-1167.2008.01680.x","volume":"49","author":"R Caplan","year":"2008","unstructured":"Caplan R, et al. Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities. Epilepsia. 2008;49:1838\u201346.","journal-title":"Epilepsia"},{"key":"325_CR65","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/archpedi.1997.02170390042008","volume":"151","author":"EC Wirrell","year":"1997","unstructured":"Wirrell EC, et al. Long-term psychosocial outcome in typical absence epilepsy. Sometimes a wolf in sheeps\u2019 clothing. Arch Pediatr Adolesc Med. 1997;151:152\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"325_CR66","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ana.410350506","volume":"35","author":"S Shinnar","year":"1994","unstructured":"Shinnar S, et al. Discontinuing antiepileptic drugs in children with epilepsy: a prospective study. Ann Neurol. 1994;35:534\u201345.","journal-title":"Ann Neurol"},{"key":"325_CR67","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ejpn.2012.02.002","volume":"16","author":"A Verrotti","year":"2012","unstructured":"Verrotti A, et al. Antiepileptic drug withdrawal in childhood epilepsy: what are the risk factors associated with seizure relapse? Eur J Paediatr Neurol. 2012;16:599\u2013604.","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-019-00325-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T09:37:36Z","timestamp":1694597856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-019-00325-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1007\/s40272-019-00325-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"8 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the publication of this review. Dr. Kessler has received funding from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) for work related to Childhood Absence Epilepsy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Kessler and Dr McGinnis have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}